Astellas Pharma Europe registered and launched luteinizing hormone-releasing hormone (LHRH) agonist Eligard in majority of European countries.
Under the terms of the new agreement, the commercialization of Eligard will be expanded to the Middle East, North Africa, CIS, Central Asia and Asian markets such as China, Taiwan, Thailand, Hong Kong, the Philippines and Indonesia.
The new agreement could strengthen the presence of the therapeutic area, as well as a bridgehead for the entry into the therapeutic area of oncology, Astellas’ third prioritized area alongside urology and transplant in emerging markets including Asia.